Building a Model for Mapping Gene Tic Variation Affecting

Total Page:16

File Type:pdf, Size:1020Kb

Building a Model for Mapping Gene Tic Variation Affecting BUILDING A MODEL FOR MAPPING GENETIC VARIATION AFFECTING GENE EXPRESSION by Peter Daniel Lee Department of Human Genetics, McGill University, Montreal February 2005 A thesis submitted to Mc Gill University in partial fulfillment of the requirements of the degree ofPh.D. ©Peter Daniel Lee, 2005 Library and Bibliothèque et 1+1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de l'édition 395 Wellington Street 395, rue Wellington Ottawa ON K1A ON4 Ottawa ON K1A ON4 Canada Canada Your file Votre référence ISBN: 978-0-494-21668-2 Our file Notre référence ISBN: 978-0-494-21668-2 NOTICE: AVIS: The author has granted a non­ L'auteur a accordé une licence non exclusive exclusive license allowing Library permettant à la Bibliothèque et Archives and Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par télécommunication ou par l'Internet, prêter, telecommunication or on the Internet, distribuer et vendre des thèses partout dans loan, distribute and sell th es es le monde, à des fins commerciales ou autres, worldwide, for commercial or non­ sur support microforme, papier, électronique commercial purposes, in microform, et/ou autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriété du droit d'auteur ownership and moral rights in et des droits moraux qui protège cette thèse. this thesis. Neither the thesis Ni la thèse ni des extraits substantiels de nor substantial extracts from it celle-ci ne doivent être imprimés ou autrement may be printed or otherwise reproduits sans son autorisation. reproduced without the author's permission. ln compliance with the Canadian Conformément à la loi canadienne Privacy Act some supporting sur la protection de la vie privée, forms may have been removed quelques formulaires secondaires from this thesis. ont été enlevés de cette thèse. While these forms may be included Bien que ces formulaires in the document page count, aient inclus dans la pagination, their removal does not represent il n'y aura aucun contenu manquant. any loss of content from the thesis. ••• Canada ~. PREFACE 1 At the start of this degree, DNA microarrays were still emerging on the scientific stage. Since then much has changed. Initial microarray studies inspired the imagination - we imagined that we were viewing the global machinery of the cell for the first time. Would it be possible to understand the entire gene network? As the technology evolved, this enthusiasm has been followed by the realization that statistical evaluations were needed. This has not replaced the questions raised during the initial phase of inspiration but rather made us aware ofhow challenging it will be to answer such questions convincingly, even at aIl. Over the course of this thesis l observed the evolution of a technology, a process whereby multiple disciplines interacted to develop a common vocabulary. Many questions remain. l have addressed a small fraction of the field in my thesis; the scope of this experiment is already vast beyond the imagination. Along the way, a great number of analytical tools were developed and applied. The following chapters coyer my own process of evolution in the understanding and application of these techniques to address biological questions. Along the way l have received help from many sources. l present a partiallist of names to acknowledge the individuals who, without their support, this degree would not have been possible: my supervisors Thomas Hudson, Michael Hallett, members ofmy advisory committee, Marcel Behr, Patricia Tonin; at the McGill University and Genome Quebec Centre for Innovation, Rob Sladek, Jaroslav Novak, Celia Greenwood, Tomi Pastinen, Bing Ge, Bob Nadon, Pierre Lepage, Jamie Engert, Chon Loredo-Osti, Jenny Koulis, 2 Andrei Verner, Tibor van Rooij, Donna Sinnett, Sebastien Brunet, Vincenzo Forgetta, Janet Faith, Sebastien de Grandpre; members of the McGill Centre for Bioinformatics, Marina Takane, Greg Finak, Francois Pepin, Michelle Scott, Ernesto Iacucci, Trevor Bruen, Rachel Bevan, Kaleigh Smith; members of the MUHC Emil Skamene, Serge Mostowy; the Human Genetics Student Society, in particular, Emily Manderson, Judith Caron, Caroline Gallant and Vanessa Sancho, co-organizers of the Bioinformatics Research Day; the laboratory of Alan Peterson; the Animal Facility at the Montreal General Hospital Research Institute; Laura Benner, Fran Langton at the Dept ofHuman Genetics; Leon Glass, and Michael Mackey at the Centre for Nonlinear Dynamics; Pablo Tamayo, Todd Golub, Bing Ren, David DeGraffe at the WhiteheadlMIT Center for Genome Research and Michael Rebhan at Astra-Zeneca who provided stimulating discussions at the start of this degree; Spyro Mousses at TGEN and Hilmi Ozcelik at the University of Toronto for continued encouragement along the way; Prof Charles J. Lumsden of the University of Toronto who first made me aware ofbioinformatics and the importance of imagination in science; Jerome Holmes, Johanne O'Malley and the staff of Thomson House for unwavering their support, the Post Graduate Student Society, an example of graduate student governance beyond compare - Thomson House and the PGSS represent environments for interdisciplinary interaction, applied learning, and are among the highest benefits of pursuing graduate studies at McGill. Thanks to those who read and edited this thesis, Tom Hudson, Rob Sladek, Jamie Engert, Anny Fortin, Celia Greenwood and Pierre Lepage, who provided the French translation of the abstracto Special thanks to Monica Herman for her help in times of need. There are many others, Cathy Neighbor, Paul Shoniker, Julia Shiu, Martha Shiu. l thank you aIl. 3 For my sister, Mary-Esther Lee and in memory ofmy mom, Esther Kuo Wah Lee, my dad, Rev. David Yiu Shan Lee, and my brother, John David Lee. 4 r--' TABLE OF CONTENTS PREFACE 2 TABLE OF CONTENTS 5 CONTRIBUTIONS OF AUTHORS 7 ABBREVIATIONS 10 ABSTRACT (ENGLISH) 12 RÉSUMÉ (FRANÇAIS) 14 INTRODUCTION 16 PART 1. BIOLOGICAL MODELS 16 PART 2. GENETICS OF GENE REGULATION 19 PART 3. MICROARRAy TECHNOLOGY 26 PART 4. INBRED MICE 30 .~ PART 5. INTEGRATIVE APPROACHES 32 PART 6. THESIS OBJECTIVES 35 CHAPTER 1-UNDERSTANDING THE SYSTEM: CONTROLS IN MICROARRAY EXPERIMENTS 36 CONTROL GENES AND VARIABILITY: ABSENCE OF UBIQUITOUS REFERENCE TRANSCRIPTS IN DIVERSE MAMMALIAN EXPRESSION STUDIES 39 ABSTRACT 40 INTRODUCTION 41 METRODS 42 RESULTS AND DISCUSSION 44 FIGURE LEGENDS 57 CHAPTER 2 - APPLICATION TO EXPERIMENTAL SYSTEMS: GENE EXPRESSION ANALYSIS OF INBRED MOUSE STRAINS 66 TISSUE-SPECIFIC DIFFERENCES IN BASAL GENE EXPRESSION BETWEEN AlJ AND C57BL/6J INBRED MOUSE STRAINS. 70 ABSTRACT 71 INTRODUCTION 72 MATERIALS AND METRODS 75 RESULTS 78 DISCUSSION 80 FIGURE LEGENDS 97 5 CHAPTER 3 - INTEGRATIVE APPROACHES TO DETECTING CIS- REGULATORY VARIATION ACROSS THE MOUSE GENOME 113 ENRICHED DETECTION OF GENES WITH ALLELE-SPECIFIC EXPRESSION DIFFERENCES BY EXPRESSION PROFILING IN RECOMBINANT CONGENIC STRAINS 116 ABSTRACT 117 INTRODUCTION 118 MATERIAL AND METHODS 122 RESULTS 125 DISCUSSION 129 FIGURE LEGENDS 141 GENERAL DISCUSSION 154 CONCLUSIONS 167 REFERENCES 170 APPENDIX A. REVIEW ARTICLE - LA PUCE À ADN EN MÉDECINE ET EN SCIENCE. 188 APPENDIX B. LABORATORY AND ANIMAL USE ETHICS APPROV ALS 189 6 CONTRIBUTIONS OF AUTHORS Mouse Work AIJ and C57BL/6J mice as weIl as the Recombinant Congenic Panel were provided by Dr Emil Skamene and Dr Anny Fortin. Genotyping data for the RCS panel were provided following a Material Transfer Agreement with Emerillon Therapeutics. Housing, sacrificing and tissue dissections were performed by staff at the MUHC Mouse FaciHty managed by Jean-Marie Chavannes. RNA extractions were performed by technicians Scott Gurd and Yannick Fortin, Dr Rob Sladek, graduate student Sarav Sundararajan and myself. Microarray Hybridizations Microarray hybridizations were performed by Dr Rob Sladek, Yannick Fortin, Daniel Vincent and Arek Siwoski in the Chip Facility at the Mc Gill University and Genome Quebec Innovation Centre. Bioinformatics and Infrastructure l handled aIl programming for analysis of microarray data including parsing of data files using Perl, statistical analysis in SAS and R, incorporation of information from other biological databases, constructing a database for the ReS project and design of web interfaces for analyzing data. Bing Ge provided the positions of Affymetrix oligonucleotides and microsatellites from the RCS project, aligned to the UCSC mouse genome assembly. Tibor van Rooji assisted me in setting up databases and with Perl 7 programming. Peter Nowacki set up the lab's first server and infrastructure of critical importance to my work from 1999 to 2002. Marina Takane, M.Sc. graduate in the laboratory of Dr Mike Hallett, was involved in the early part of the RCS project in formulating proposaIs to search for trans-regulatory relationships, and was involved in designing programs to assign DSO to genes. Greg Finàk, Ph.D. candidate in the laboratory of Drs Morag Park and Mike Hallett, assisted me with statistics programming in R. Ernesto Iacucci, M.Sc. candidate in the laboratory ofDrs Hans Zingg and Mike Hallett, provided advice on the use of the Gene Ontology database. The McGill Centre for Bioinformatics provided critical infrastructure in the form of servers, databases, and computational power. AlI computationaIly intensive analyses were performed on this infrastructure from 2002-2005. Francois
Recommended publications
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Dynamic Transcriptomic Profiles of Zebrafish Gills in Response to Zinc
    Zheng et al. BMC Genomics 2010, 11:548 http://www.biomedcentral.com/1471-2164/11/548 RESEARCH ARTICLE Open Access Dynamic transcriptomic profiles of zebrafish gills in response to zinc depletion Dongling Zheng1,4, Peter Kille2, Graham P Feeney2, Phil Cunningham1, Richard D Handy3, Christer Hogstrand1* Abstract Background: Zinc deficiency is detrimental to organisms, highlighting its role as an essential micronutrient contributing to numerous biological processes. To investigate the underlying molecular events invoked by zinc depletion we performed a temporal analysis of transcriptome changes observed within the zebrafish gill. This tissue represents a model system for studying ion absorption across polarised epithelial cells as it provides a major pathway for fish to acquire zinc directly from water whilst sharing a conserved zinc transporting system with mammals. Results: Zebrafish were treated with either zinc-depleted (water = 2.61 μgL-1; diet = 26 mg kg-1) or zinc-adequate (water = 16.3 μgL-1; diet = 233 mg kg-1) conditions for two weeks. Gill samples were collected at five time points and transcriptome changes analysed in quintuplicate using a 16K oligonucleotide array. Of the genes represented the expression of a total of 333 transcripts showed differential regulation by zinc depletion (having a fold-change greater than 1.8 and an adjusted P-value less than 0.1, controlling for a 10% False Discovery Rate). Down-regulation was dominant at most time points and distinct sets of genes were regulated at different stages. Annotation enrichment analysis revealed that ‘Developmental Process’ was the most significantly overrepresented Biological Process GO term (P = 0.0006), involving 26% of all regulated genes.
    [Show full text]
  • Predicting Clinical Response to Treatment with a Soluble Tnf-Antagonist Or Tnf, Or a Tnf Receptor Agonist
    (19) TZZ _ __T (11) EP 2 192 197 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.06.2010 Bulletin 2010/22 C12Q 1/68 (2006.01) (21) Application number: 08170119.5 (22) Date of filing: 27.11.2008 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AT BE BG CH CY CZ DE DK EE ES FI FR GB GR yet been filed HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR (74) Representative: Habets, Winand Designated Extension States: Life Science Patents AL BA MK RS PO Box 5096 6130 PB Sittard (NL) (71) Applicant: Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg 1081 HV Amsterdam (NL) (54) Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist (57) The invention relates to methods for predicting a clinical response to a therapy with a soluble TNF antagonist, TNF or a TNF receptor agonist and a kit for use in said methods. EP 2 192 197 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 192 197 A1 Description [0001] The invention relates to methods for predicting a clinical response to a treatment with a soluble TNF antagonist, with TNF or a TNF receptor agonist using expression levels of genes of the Type I INF pathway and a kit for use in said 5 methods. In another aspect, the invention relates to a method for evaluating a pharmacological effect of a treatment with a soluble TNF antagonist, TNF or a TNF receptor agonist.
    [Show full text]
  • Highly Frequent Allelic Loss of Chromosome 6Q16-23 in Osteosarcoma: Involvement of Cyclin C in Osteosarcoma
    1153-1158 5/11/06 16:31 Page 1153 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 18: 1153-1158, 2006 Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: Involvement of cyclin C in osteosarcoma NORIHIDE OHATA1, SACHIO ITO2, AKI YOSHIDA1, TOSHIYUKI KUNISADA1, KUNIHIKO NUMOTO1, YOSHIMI JITSUMORI2, HIROTAKA KANZAKI2, TOSHIFUMI OZAKI1, KENJI SHIMIZU2 and MAMORU OUCHIDA2 1Science of Functional Recovery and Reconstruction, 2Department of Molecular Genetics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama 700-8558, Japan Received June 13, 2006; Accepted August 14, 2006 Abstract. The molecular pathogenesis of osteosarcoma is very rearrangements (1,2). It has been reported that both RB1 and complicated and associated with chaotic abnormalities on many TP53 pathways are inactivated, and the regulation of cell cycle chromosomal arms. We analyzed 12 cases of osteosarcomas is impaired in most osteosarcomas (1). For example, deletion/ with comparative genomic hybridization (CGH) to identify mutation of the CDKN2A gene encoding both p16INK4A and chromosomal imbalances, and detected highly frequent p14ARF on 9p21 (3-5), amplification of the CDK4 (6), CCND1, chromosomal alterations in chromosome 6q, 8p, 10p and MDM2 genes (4), and other aberrations related to inactivation 10q. To define the narrow rearranged region on chromosome 6 of these pathways have been found. Tumor suppressor genes with higher resolution, loss of heterozygosity (LOH) analysis (TSGs) are suspected to be involved in tumorigenesis of was performed with 21 microsatellite markers. Out of 31 cases, osteosarcoma. Loss of heterozygosity (LOH) studies have 23 cases (74%) showed allelic loss at least with one marker on detected frequent allelic loss at 3q, 13q, 17p and 18q (7).
    [Show full text]
  • Table of Contents Table of Contents
    Table of contents Table of contents................................................................................................................. 1 Summary ............................................................................................................................. 3 Abbreviations ...................................................................................................................... 4 Gene Symbols I - Incidentals .............................................................................................. 5 Gene symbols II - Target Gene Names ............................................................................... 6 1. Introduction........................................................................................................... 12 1.1. The Pathos of the Crab ..................................................................................... 12 1.2. Cancer in the Molecular Age - a genetic and epigenetic disease..................... 13 1.3. Tumoral evolution............................................................................................. 14 1.4. DNA repair systems .......................................................................................... 17 1.4.1. DNA Mismatch Repair.............................................................................. 18 1.4.2. Double-strand Break Repair..................................................................... 19 1.4.3. Direct Repair...........................................................................................
    [Show full text]
  • Supplementary Tables S1-S3
    Supplementary Table S1: Real time RT-PCR primers COX-2 Forward 5’- CCACTTCAAGGGAGTCTGGA -3’ Reverse 5’- AAGGGCCCTGGTGTAGTAGG -3’ Wnt5a Forward 5’- TGAATAACCCTGTTCAGATGTCA -3’ Reverse 5’- TGTACTGCATGTGGTCCTGA -3’ Spp1 Forward 5'- GACCCATCTCAGAAGCAGAA -3' Reverse 5'- TTCGTCAGATTCATCCGAGT -3' CUGBP2 Forward 5’- ATGCAACAGCTCAACACTGC -3’ Reverse 5’- CAGCGTTGCCAGATTCTGTA -3’ Supplementary Table S2: Genes synergistically regulated by oncogenic Ras and TGF-β AU-rich probe_id Gene Name Gene Symbol element Fold change RasV12 + TGF-β RasV12 TGF-β 1368519_at serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 ARE 42.22 5.53 75.28 1373000_at sushi-repeat-containing protein, X-linked 2 (predicted) Srpx2 19.24 25.59 73.63 1383486_at Transcribed locus --- ARE 5.93 27.94 52.85 1367581_a_at secreted phosphoprotein 1 Spp1 2.46 19.28 49.76 1368359_a_at VGF nerve growth factor inducible Vgf 3.11 4.61 48.10 1392618_at Transcribed locus --- ARE 3.48 24.30 45.76 1398302_at prolactin-like protein F Prlpf ARE 1.39 3.29 45.23 1392264_s_at serine (or cysteine) peptidase inhibitor, clade E, member 1 Serpine1 ARE 24.92 3.67 40.09 1391022_at laminin, beta 3 Lamb3 2.13 3.31 38.15 1384605_at Transcribed locus --- 2.94 14.57 37.91 1367973_at chemokine (C-C motif) ligand 2 Ccl2 ARE 5.47 17.28 37.90 1369249_at progressive ankylosis homolog (mouse) Ank ARE 3.12 8.33 33.58 1398479_at ryanodine receptor 3 Ryr3 ARE 1.42 9.28 29.65 1371194_at tumor necrosis factor alpha induced protein 6 Tnfaip6 ARE 2.95 7.90 29.24 1386344_at Progressive ankylosis homolog (mouse)
    [Show full text]
  • Interventions to Increase Apolipoprotein A-I Transcription in Hepg2 Cells
    Interventions to increase apolipoprotein A-I transcription in HepG2 cells Citation for published version (APA): van der Krieken, S. E. (2017). Interventions to increase apolipoprotein A-I transcription in HepG2 cells. Uitgeverij BOXPress. https://doi.org/10.26481/dis.20170330svdk Document status and date: Published: 01/01/2017 DOI: 10.26481/dis.20170330svdk Document Version: Publisher's PDF, also known as Version of record Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website. • The final author version and the galley proof are versions of the publication after peer review. • The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.
    [Show full text]
  • Thom Ulullallittur
    THOMULULLALLITTUR US009737480B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 ,737 ,480 B2 Lu et al. (45 ) Date of Patent: Aug. 22 , 2017 ( 54 ) ARRDC1-MEDIATED MICROVESICLES 2014 /0273226 AL 9 /2014 Wu 2014 /0364588 A1 12 / 2014 Haugwitz et al. ?? (ARMMS ) AND USES THEREOF 2016 / 0206566 AL 7 / 2016 Lu et al. ( 71 ) Applicants : President and Fellows of Harvard College , Cambridge, MA (US ) ; The FOREIGN PATENT DOCUMENTS Board of Trustees of the Leland WO WO 2011 / 127219 10 /2011 Stanford Junior University , Palo Alto , WO WO 2013 / 119602 8 / 2013 CA (US ) WO WO 2014 /093655 6 / 2014 (72 ) Inventors : Quan Lu , Newton , MA (US ) ; Joseph OTHER PUBLICATIONS F . Nabhan , Cambridge , MA (US ) ; Stanley N . Cohen , Stanford , CA (US ) Properzi et al . , Biomarkers Med . 2013 , 7 ( 5 ) 769 - 778 . * Kosaka et al. J . Biol. Chem 2010 , 285 : 17442 - 17452 . * International Search Report and Written Opinion for PCT/ US2013 / ( 73 ) Assignees : President and Fellows of Harvard 024839 , mailed May 28 , 2013 . College, Cambridge , MA (US ) ; The International Preliminary Report on Patentability for PCT /US2013 / Board of Trustees of the Leland 024839 , mailed Aug . 21 , 2014 . Standford Junior University , Stanford , Genbank Submission ; NIH /NCBI , Accession No. NP _ 689498 . CA (US ) Puca et al ., Mar. 22 , 2014 . Genbank Submission ; NIH /NCBI , Accession No. NP _ 001155957 . ( * ) Notice : Subject to any disclaimer , the term of this Skarnes et al. , Feb . 26 , 2014 . patent is extended or adjusted under 35 Genbank Submission ; NIH /NCBI , Accession No . NP _ 848495 . ? U . S . C . 154 ( b ) by 0 days . Skarnes et al ., Feb . 26 , 2014 .
    [Show full text]
  • Epithelial-Mesenchymal Transition Cross-Journal Focus EMT Epithelial-Mesenchymal Transition
    EMBO Molecular Medicine cross-journal focus EMT Epithelial-Mesenchymal Transition cross-journal focus EMT Epithelial-Mesenchymal Transition EDITORS David del Alamo Editor [email protected] | T +49 6221 8891 309 David received his PhD. from the Madrid’s Autónoma University where he studied proximal-distal patterning in Drosophila with Fernando Díaz-Benjumea. As a postdoc, he continued working with Drosophila, first in Marek Mlodzik’s lab (Mount Sinai School of Medicine, New York) on the mechanisms of epithelial planar cell polarity generation, and then with François Schweisguth (Institut Pasteur, Paris) where he focused on the modulation of Notch signalling in lateral inhibition. David joined The EMBO Journal in 2011. Nonia Pariente Senior Editor [email protected] | T +49 6221 8891 305 Nonia joined EMBO Reports in August 2007. She studied biochemistry and molecular biology in Madrid’s Autónoma University, where she also gained her PhD on the generation of new antiviral strategies against RNA viruses. She did a four-year post-doc at UCLA focusing on the development of new strategies for gene therapy. Roberto Buccione Editor [email protected] | T +49 6221 8891 310 Roberto Buccione completed his PhD at the University of l’Aquila, Italy studying the process of oogenesis in mammals. After continuing these studies as a post-doctoral researcher at the EMBO Jackson Laboratory, Bar Harbor ME, USA, he joined the Mario Negri Sud research institute in S. Molecular Maria Imbaro, Italy, where he lead a research group focused on the cell biology of tumour cell Medicine invasion. He joined EMBO Molecular Medicine as a Scientific Editor in October 2012.
    [Show full text]
  • Characterising Response and Resistance Mechanisms to Faslodex in Breast Cancer
    Characterising response and resistance mechanisms to Faslodex in breast cancer Hayley Elizabeth Francies A thesis presented for the degree of Doctor of Philosophy at Cardiff University September 2013 Breast Cancer Molecular and Pharmacology Group School of Pharmacy and Pharmaceutical Sciences Redwood Building Cardiff University King Edward VII Avenue Cardiff, CF103NB i Abstract In ER+ breast cancer initial responses to antihormones are variable, complete responses are rare and resistance is eventually acquired by many patients. It is important to model these events to discover predictive markers of antihormone outcome and so targeted strategies can be developed to maximise antihormone effectiveness. To date, most studies have employed the MCF-7 cell line which fails to represent the variability of ER+ disease. Focusing on Faslodex, the thesis objective was to use 4 cell lines in vitro encompassing ER+/HER2- (MCF-7/T47D) and ER+/HER2+ (BT474/MDA-MB-361) disease to (i) characterise the magnitude of initial antihormone response, (ii) monitor the onset of resistance by prolonged treatment and (iii) detail gene expression changes during Faslodex treatment. All models were initially growth-inhibited by Faslodex, with superior responses in HER2- lines. Microarray analysis revealed gene cohorts affected by Faslodex treatment differed between HER2+ and HER2- models. While MCF-7, BT474 and MDA-MB-361 cells acquired Faslodex resistance, this failed to develop in the T47D line, providing a model of complete-response. A filtering process identified genes involved in the varying Faslodex responses and clinical relevance was determined using the NEWEST Faslodex clinical trial dataset. Of interest was the Faslodex-induction of CXCR4, as a potential mediator of acquired resistance, while suppression of the RET signalling pathway related to improved initial response in the ER+/HER2- setting.
    [Show full text]
  • Identification of Thioredoxin-Interacting Protein (TXNIP) As a Downstream Target for IGF1 Action
    Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action Karthik Nagaraja, Lena Lapkina-Gendlera, Rive Sarfsteina, David Gurwitza, Metsada Pasmanik-Chorb, Zvi Laronc, Shoshana Yakard, and Haim Wernera,e,1 aDepartment of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel; bBioinformatics Unit, George Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv, Israel; cEndocrine and Diabetes Research Unit, Schneider Children’s Medical Center, 49292 Petah Tikva, Israel; dDavid B. Kriser Dental Center, Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY; and eYoran Institute for Human Genome Research, Tel Aviv University, 69978 Tel Aviv, Israel Edited by Dennis A. Carson, University of California, San Diego, La Jolla, CA, and approved December 20, 2017 (received for review September 12, 2017) Laron syndrome (LS), or primary growth hormone (GH) insensitiv- Of interest, about 15% of the genes are involved in metabolic path- ity, is the best-characterized entity among the congenital insulin- ways. Given the key role of IGF1 in regulation of cancer cell me- like growth factor 1 (IGF1) deficiencies. Life-long exposure to tabolism, it is reasonable to assume that alteration in the expression of minute endogenous IGF1 levels is linked to low stature as well as a IGF1-dependent metabolic genes may constitute an important mech- number of endocrine and metabolic abnormalities. While elevated anism that contributes to establishment of a malignant phenotype. IGF1 is correlated with increased cancer incidence, epidemiological Thioredoxin-interacting protein (TXNIP) was initially discov- studies revealed that patients with LS do not develop tumors.
    [Show full text]
  • Kisspeptin/KISS1R System in Breast Cancer Donna Cvetković 1, Andy V
    Journal of Cancer 2013, Vol. 4 653 Ivyspring International Publisher Journal of Cancer 2013; 4(8): 653-661. doi: 10.7150/jca.7626 Review Kisspeptin/KISS1R System in Breast Cancer Donna Cvetković 1, Andy V. Babwah 1,2,3,4 and Moshmi Bhattacharya 1, 3, 5 1. Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, N6A 5C1; 2. The Children’s Health Research Institute, London, Ontario, Canada; 3. Lawson Health Research Institute, London, Ontario, Canada; 4. Department of Obstetrics and Gynaecology, University of Western Ontario London, Ontario, Canada N6C 2V5; 5. Department of Oncology, University of Western Ontario, London, Ontario, Canada. Corresponding author: Dr. Moshmi Bhattacharya, Department of Physiology and Pharmacology, Medical Sciences Building, MSB 216, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, N6A 5C1. Tel: 519-661-2111, ext. 82970; Fax: 519-661-3827 E-mail: [email protected]. © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2013.09.10; Accepted: 2013.09.22; Published: 2013.09.26 Abstract Kisspeptins (KP), peptide products of the kisspeptin-1 (KISS1) gene are the endogenous ligands for a G protein-coupled receptor (GPCR) – KP receptor (KISS1R). KISS1R couples to the Gαq/11 signaling pathway. KISS1 is a metastasis suppressor gene and the KP/KISS1R signaling has an- ti-metastatic and tumor-suppressant effects in numerous human cancers.
    [Show full text]